G1 Therapeutics (GTHX)
(Delayed Data from NSDQ)
$3.19 USD
+0.20 (6.69%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $3.19 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
D Value D Growth C Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
GTHX 3.19 +0.20(6.69%)
Will GTHX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for GTHX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for GTHX
G1 Therapeutics (GTHX) Reports Q1 Loss, Lags Revenue Estimates
G1 Therapeutics (GTHX) Reports Q4 Loss, Tops Revenue Estimates
GTHX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Dynavax Technologies (DVAX) Expected to Beat Earnings Estimates: Should You Buy?
Will G1 Therapeutics (GTHX) Report Negative Earnings Next Week? What You Should Know
G1 Therapeutics (GTHX) Tops Q2 Earnings and Revenue Estimates
Other News for GTHX
Catalyst Watch: Tesla deliveries, Constellation Brands earnings, and the June Jobs Report
G1 Therapeutics price target lowered by $6 at Needham, here's why
Ball To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Tuesday
G1 Therapeutics drops as breast cancer therapy fails in late-stage trial
Maintaining Buy Rating on G1 Therapeutics: Strategic Realignment and Cosela’s Commercial Promise Despite Clinical Trial Setback